A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease

American Journal of Managed Care

Volumn 13, Issue 3, 2007, Pages 142-147

  Berthiaume, John T ^a   Davis, Jim ^a   Taira, Deborah A ^b,c   Thein, Ko Ko ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Hawaii Medical Service Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CORONARY ARTERY DISEASE; DRUG UTILIZATION; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE MANAGEMENT; DRUG UTILIZATION REVIEW; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33947225618     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, Tex: American Heart Association; 2006.
2. Burch S, Ou N. Current indications for ACE inhibitors and HOPE for the future. Am J Manag Care. 2002;8:478-490.
3. Horwich TB, Fonarow GC. Prevention of heart failure. Curr Cardiol Rep. 2002;4:194-199.
4. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. β-Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
5. Wikstrand J, Warnold I, Olsson G. Toumilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. JAMA. 1988;259:1976-1982.
6. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. Circulation. 1994;90:762-768.
7. Auer J, Eber B. A clinical focus on statins. Curr Opin Investig Drugs. 2001;2:382-388.
8. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109:745-749.
9. 2). Circulation. 2002;106:1909-1912.
10. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19:638-645.
11. Goff DC Jr, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research Through Technology (HEART) trial. Am Heart J. 2003;146:1045-1051.
12. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med. 1999;159:561-567.
13. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2000. J Am Coll Cardiol. 2003;41:56-61.
14. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ. 2004;328:693-697.
15. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of β-blockers in survivors of acute myocardial infarction. Am J Health Syst Pharm. 2002;59:2226-2232.
16. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of under treatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
18. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study [published correction appears in Circulation. 1996;94:849]. Circulation. 1996;93:1796-1802.
19. Muhlestein JB, Home BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257-261.
20. Shalowitz M, Heaton AH. Cost effectiveness of risk reduction: the managed care perspective. Am J Med. 1996;101:4A71S-4A75S.
21. Mukherjee D, Eagle KA. Improving quality of care in the real world: efficacy versus effectiveness? Am Heart J. 2003;146:946-947.